HCG Education

HCG vs Clomid vs Nolvadex: Which PCT Compound Does What and When to Use Each

The three most widely used compounds in post-cycle therapy are human chorionic gonadotropin (HCG), clomiphene citrate (Clomid), and tamoxifen citrate (Nolvadex). Each one works through a different mechanism, targets a different part of the hormonal recovery chain, and carries its own set of trade-offs. Choosing the wrong compound, or using the right one at the wrong time, can slow your recovery instead of speeding it up. This guide from GenXtropin UK breaks down exactly how each compound works at the receptor level, what the clinical evidence says about each one, and how they fit together in a complete PCT protocol. For a detailed explanation of HCG specifically, see our complete HCG guide.

The Three Levels of the HPG Axis and Which Compound Targets Each One

To understand why these three compounds are used together rather than interchangeably, you need to understand the three levels of the hypothalamic-pituitary-gonadal (HPG) axis. Anabolic steroids suppress all three levels simultaneously. Effective PCT needs to address each level with the right tool.

Level 1: Hypothalamus (GnRH production)

The hypothalamus produces gonadotropin-releasing hormone (GnRH) in pulses. Estrogen from aromatised testosterone feeds back to the hypothalamus and suppresses GnRH output. During a steroid cycle, high estrogen levels from aromatisation shut down GnRH pulsatility almost entirely. Clomid and Nolvadex target this level by blocking estrogen receptors in the hypothalamus, which removes the negative feedback and allows GnRH production to resume.

Level 2: Pituitary (LH and FSH production)

The anterior pituitary responds to GnRH by producing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Estrogen also feeds back directly to the pituitary to suppress LH and FSH release. Clomid and Nolvadex also target this level by blocking estrogen receptors at the pituitary, which increases LH and FSH output once GnRH signalling has been restored.

Level 3: Testes (Testosterone production)

The Leydig cells in the testes produce testosterone in response to LH. After prolonged steroid use without stimulation, the Leydig cells atrophy and become less responsive. Even if the pituitary starts producing LH again, atrophied Leydig cells may respond slowly or inadequately. HCG targets this level by binding directly to the LH/CG receptor on Leydig cells and stimulating testosterone production, bypassing the hypothalamus and pituitary entirely.

This is why the three compounds are complementary rather than substitutes. HCG restores testicular function from the bottom up. Clomid and Nolvadex restore hypothalamic-pituitary signalling from the top down. Using only one leaves at least one level of the axis unaddressed.

HCG: Direct Testicular Stimulation

HCG is a glycoprotein hormone that mimics LH at the testicular level. It binds to the LH/CG receptor on Leydig cells and triggers the cAMP/PKA signalling cascade that produces testosterone. Its terminal half-life is 29 to 37 hours, far longer than endogenous LH at roughly 20 to 30 minutes, which is why it can be dosed two to three times per week rather than continuously.

A study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that low-dose HCG (250 to 500 IU) administered during exogenous testosterone use maintained intratesticular testosterone levels. The placebo group saw a 94% decline. The 250 IU group saw only a 7% decline. The 500 IU group actually increased intratesticular testosterone by 26% above baseline. This data directly supports the use of HCG during a steroid cycle to keep Leydig cells functional.

The trade-off with HCG is that it stimulates intratesticular aromatase, which increases estrogen production. It also does not address the hypothalamic-pituitary suppression. HCG provides testosterone but does not restart the signalling chain that produces LH naturally. This is why HCG is used first (or on-cycle) and then transitioned to SERMs, not used indefinitely. Excessive HCG doses or prolonged use leads to Leydig cell desensitization, as documented in research published in the Journal of Biological Chemistry. GENX-HCG is available through the GenXtropin store. Full details on HCG dosing, timing, and the desensitization mechanism are covered in our HCG PCT guide.

Clomid (Clomiphene Citrate): Hypothalamic-Pituitary Recovery

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors in the hypothalamus and pituitary. A 2024 review published in Pharmaceuticals (MDPI) described clomiphene as a promising alternative to testosterone replacement therapy for male hypogonadism specifically because it stimulates endogenous testosterone production rather than replacing it with exogenous hormone.

The mechanism is straightforward. Clomiphene occupies estrogen receptors in the hypothalamus and depletes them. This removes the negative feedback signal that circulating estradiol normally provides. The hypothalamus, no longer detecting adequate estrogen, increases GnRH pulse frequency. The pituitary responds by increasing LH and FSH output. A landmark study published in the Journal of Clinical Investigation measured this effect in healthy men: three weeks of clomiphene treatment at 100 mg daily produced a threefold increase in circulating LH, an 80% increase in LH pulse frequency, a 70% increase in LH pulse amplitude, a threefold increase in FSH, and a twofold increase in both testosterone and estradiol.

Clomiphene is available as two isomers: enclomiphene (the anti-estrogenic isomer) and zuclomiphene (which has mixed estrogenic and anti-estrogenic properties). Standard clomiphene citrate contains both isomers. The zuclomiphene component is responsible for most of clomiphene’s reported side effects, including visual disturbances (blurred vision, floaters), mood swings, and emotional lability. These side effects are dose-dependent and generally resolve after discontinuation.

Nolvadex (Tamoxifen Citrate): Targeted Estrogen Blockade

Tamoxifen is also a SERM, but it has a different receptor binding profile than clomiphene. It is a pure estrogen antagonist at the breast and hypothalamus but has partial estrogenic activity in certain other tissues such as bone and liver. According to the DrugBank tamoxifen profile, its primary clinical use is as an adjuvant treatment for estrogen receptor-positive breast cancer, where it has decades of safety data in long-term use.

In PCT, tamoxifen works at the same hypothalamic-pituitary level as clomiphene: it blocks estrogen receptors, removes negative feedback, and allows GnRH, LH, and FSH production to resume. Clinical data has shown that 20 mg of tamoxifen daily produces a moderate increase in LH, FSH, testosterone, and estradiol in healthy men, comparable to the effect of 150 mg of clomiphene citrate. This suggests tamoxifen is roughly 7.5 times more potent by weight at the hypothalamic-pituitary level, although direct comparison is complicated by the different receptor selectivity profiles of the two compounds.

Tamoxifen’s key practical advantage over clomiphene in PCT is its side effect profile. Because tamoxifen does not contain the zuclomiphene isomer, it does not produce the visual disturbances and mood changes that some clomiphene users experience. For this reason, many users prefer tamoxifen for longer PCT durations. Its strong anti-estrogenic activity in breast tissue also makes it the preferred SERM for users concerned about gynecomastia during the recovery phase.

Head to Head Comparison

Property HCG Clomid (Clomiphene) Nolvadex (Tamoxifen)
Drug Class Glycoprotein hormone (LH analogue) Selective estrogen receptor modulator (SERM) Selective estrogen receptor modulator (SERM)
Target Leydig cells in the testes (LHCG receptor) Estrogen receptors in hypothalamus and pituitary Estrogen receptors in hypothalamus, pituitary, and breast tissue
Mechanism Directly stimulates testosterone production (bottom up) Blocks estrogen feedback, increases GnRH/LH/FSH (top down) Blocks estrogen feedback, increases GnRH/LH/FSH (top down)
Administration Subcutaneous injection after reconstitution Oral tablet Oral tablet
Restores Endogenous LH No. Bypasses pituitary LH production. Yes. Stimulates pituitary to produce LH. Yes. Stimulates pituitary to produce LH.
Reverses Testicular Atrophy Yes. Primary strength. Indirectly, via restored LH. Indirectly, via restored LH.
Gynecomastia Protection No. Can increase estrogen via aromatase. Moderate. Blocks estrogen at some tissues. Strong. Potent estrogen antagonist in breast tissue.
Preserves Fertility Yes. Maintains intratesticular testosterone for spermatogenesis. Yes. Increases FSH which supports sperm production. Yes. Increases FSH similarly to clomiphene.
Risk of Desensitization Yes. Excessive doses reduce Leydig cell responsiveness. No receptor desensitization risk. No receptor desensitization risk.
Common Side Effects Increased estrogen, water retention, mood changes at high doses Visual disturbances, mood swings, emotional lability (zuclomiphene isomer) Generally better tolerated. Rare: hot flashes, joint stiffness

What the Clinical Evidence Says About Using All Three Together

A randomised study of 282 hypogonadal men published in BJU International compared clomiphene alone, HCG alone, and the combination. All three groups achieved restoration of testosterone to the normal range. However, the combination group showed significantly greater improvement in symptom scores (qADAM) at both 1 month and 3 months compared to either compound used alone. This supports the principle that addressing multiple levels of the HPG axis simultaneously produces better outcomes than targeting only one level.

A review published in Translational Andrology and Urology recommended a combination of HCG 2,000 IU every other day plus clomiphene citrate 50 mg every other day for the recovery of spermatogenesis and testosterone in men with anabolic steroid-induced hypogonadism.

In practice, many users run HCG on-cycle or during the first phase of PCT (to restore testicular function), then transition to Nolvadex or Clomid (to restore hypothalamic-pituitary signalling), and then discontinue all compounds and allow the HPG axis to function autonomously. The sequencing matters: HCG first because it directly restores what the testes have lost, SERMs second because they restart the signalling chain that will sustain natural testosterone production long-term.

When to Choose Each Compound

Use HCG when:

The testes have been suppressed for an extended period and need direct stimulation to resume function. When testicular atrophy is visible or suspected. During a cycle to prevent atrophy from occurring. When fertility preservation is a priority. When transitioning from a cycle to SERM-based PCT to provide a testosterone bridge. Available as GENX-HCG from the GenXtropin range.

Use Clomid when:

The hypothalamic-pituitary axis needs to be reactivated after HCG has restored testicular function. When endogenous LH and FSH production needs to be stimulated. When a strong gonadotropin response is needed quickly (clomiphene produces a larger magnitude LH increase than tamoxifen in some studies). When the user tolerates clomiphene without visual or mood side effects.

Use Nolvadex when:

The same hypothalamic-pituitary recovery is needed but the user experiences side effects from clomiphene (visual disturbances, mood changes). When gynecomastia prevention or reversal during PCT is a concern, as tamoxifen is a stronger estrogen antagonist in breast tissue. When a longer, lower side effect PCT is preferred. Tamoxifen is commonly run at 20 mg daily for 4 to 6 weeks.

PCT Comparison FAQ

Can I run HCG and a SERM at the same time?

+

You can, but there is a strategic reason most protocols separate them. HCG itself suppresses endogenous LH production through negative feedback (the testosterone it stimulates tells the pituitary to reduce LH output). If you run HCG and a SERM simultaneously, the SERM is trying to increase LH while the HCG-driven testosterone is telling the pituitary to decrease it. They partially counteract each other. The more effective approach is sequential: HCG first to restore testicular function, then SERMs to restart pituitary signalling after HCG is discontinued.

Is Clomid or Nolvadex better for PCT?

+

Neither is universally better. Both are SERMs that block estrogen feedback and stimulate LH and FSH production. Clomiphene tends to produce a stronger gonadotropin response in clinical studies, but it also carries more side effects due to the zuclomiphene isomer (visual disturbances, mood changes). Tamoxifen is better tolerated and provides stronger estrogen blockade in breast tissue, making it preferred when gynecomastia is a concern. Many users run both together at lower doses (such as clomiphene 25 mg daily plus tamoxifen 20 mg daily) to benefit from both profiles while minimising side effects from either.

Do I need all three compounds for PCT?

+

Not necessarily all three, but you need at least two. HCG addresses the testicular level. A SERM (either Clomid or Nolvadex) addresses the hypothalamic-pituitary level. Skipping HCG means the testes may respond slowly to restored LH because the Leydig cells have atrophied. Skipping SERMs means the pituitary may not restart LH production, and testosterone will drop again once HCG is stopped. The clinical evidence from a randomised trial in BJU International shows combination therapy outperforms single-agent therapy on symptom improvement scores.

Can I use HGH during PCT?

+

Yes. Somatropin (the active substance in GenXtropin HGH) does not interact with the HPG axis. It binds to growth hormone receptors and stimulates IGF-1 production through a completely separate pathway. HGH does not suppress LH, does not affect estrogen signalling, and does not interfere with HCG, Clomid, or Nolvadex. Many users continue HGH throughout PCT because it supports lean mass retention, fat metabolism, connective tissue health, and recovery during the vulnerable post-cycle period.

Get Your PCT Compounds Sorted

GENX-HCG and GenXtropin HGH 100IU are available from the official GenXtropin UK store. All orders ship with Royal Mail tracking and discreet packaging. Read customer reviews or contact our team for guidance.

View GENX-HCG

References

  1. Coviello, A.D., Matsumoto, A.M., Bremner, W.J. et al. “Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.” Journal of Clinical Endocrinology and Metabolism, 2005
  2. Rebois, R.V., Bhatt, R.S. “Desensitization to gonadotropins in cultured Leydig tumor cells involves loss of gonadotropin receptors and decreased capacity for steroidogenesis.” Journal of Biological Chemistry, 1987
  3. Tan, R.S., Salazar, J.A. “Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications.” Pharmaceuticals (MDPI), 2024
  4. Winters, S.J., Troen, P. “Pulsatile LH secretion in men: evidence for a role of endogenous estrogens examined by clomiphene citrate administration.” Journal of Clinical Investigation, 1990
  5. DrugBank. “Tamoxifen: Pharmacology, mechanism of action, and clinical applications.” DrugBank Online
  6. DrugBank. “Human Chorionic Gonadotropin: Drug profile and pharmacology.” DrugBank Online
  7. Helo, S., Mahon, J., Ellen, J. et al. “Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study.” BJU International, 2018
  8. Lee, J.A., Ramasamy, R. “Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men.” Translational Andrology and Urology, 2018

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
Scroll to Top